Benjamin Schlatka MBA
CEO and Co-Founder, MC10
Ben’s passion for growing and leading science-based businesses and his multidisciplinary expertise in both material science and electronics led him to co-found MC10 in 2008. Prior to MC10, Ben helped grow Nantero’s carbon nanotube electronics business (sold to Lockheed Martin Corporation) and led marketing and sales for a Volunteer Solutions.org (winner 1998 MIT 50K, sold to the United Way). He began his career as a corporate intrapreneur as one of the founding team members of IBM’s Networking Hardware microelectronics business – today greater than a billion dollars in sales. Ben’s other passion is coaching individuals on building their careers in technology and serves as an executive coach at the Harvard Business School, where he earned an MBA.
TRNDS Speaker Spotlight: Benjamin Schlatka
Meet TRNDS speaker Benjamin Schlatka, CEO and Co-Founder of MC10. MC10 uses cutting edge technology to create the most intelligent, flexible platform for biometric healthcare analytics.
Why are you participating in TRNDS 2019?
Schlatka: I am participating in TRNDS 2019, because I believe continuous clinical grade data collection outside of the clinic will revolutionize how we understand, develop and measure treatment of rare diseases.
What are biggest opportunities for accelerating therapeutic development in the 21st century?
Schlatka: The rise of digital technologies and clinical-grade wearables will revolutionize the
process of collecting and analyzing physiological data, dramatically accelerating therapy development by improving efficiency and likely increasing the success rates of clinical trials. By collecting continuous physiological data from the home, the clinical research and pharmaceutical industry will gain insights into disease states including a baseline natural history of the disease as well as therapeutic effects from where disease actually occurs – in our daily life.
How is the increasing use of modern technologies changing the field of clinical research?
Schlatka: The increasing use of clinical-grade, wearable technologies makes clinical research more efficient by providing more robust insights into disease mechanisms through higher quantity and quality data. These insights can lead to more targeted treatment methods and improved patient outcomes.
Share with us some of the most exciting developments in your organization.
Schlatka: MC10 has revolutionized data collection for clinical research and patient management by leading the migration from subjective data to objective, validated data from the home. This change will lead to a better overall understanding of disease progression and treatment efficacy, ultimately improving therapy development and patient outcomes. We are seeing adoption of this premise with major pharmaceutical customers who are leading the industry in new outcome measures.
What is a critical topic you’d like to see discussed at TRNDS 2019?
Schlatka: Rare neurological disease patients require a non-invasive, wearable method of objective data capture to help determine a natural history of their disease. An engaging discussion around FDA and industry’s perspective on this issue will help the industry more rapidly adopt these important technologies.
What challenges lie ahead in the rare disease space?
Schlatka: As more cutting-edge therapies are approved, the industry’s focus will shift to the reimbursement of rare disease treatments. MC10’s BioStamp nPoint will objectively provide medical grade, physiological data and insights that will inform the effectiveness of these important treatments in real world settings.